SEELQ (Seelos Therapeutics) Float Percentage Of Total Shares Outstanding : 99.81% (As of Mar. 05, 2025)

View and export this data going back to 1999. Start your Free Trial

What is Seelos Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Seelos Therapeutics's float shares is 0.58 Mil. Seelos Therapeutics's total shares outstanding is 0.58 Mil. Seelos Therapeutics's float percentage of total shares outstanding is 99.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Seelos Therapeutics's Insider Ownership is 92.80%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Seelos Therapeutics's Institutional Ownership is 3.55%.

Seelos Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Seelos Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.58	/	0.58
	=	99.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seelos Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seelos Therapeutics Inc (OTCPK:SEELQ) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Park Avenue, 2nd Floor, New York, NY, USA, 10022

Website

https://www.seelostherapeutics.com

Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.

Executives

Raj Mehra	director, officer: See Remarks	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Michael Joseph Golembiewski	officer: Chief Financial Officer	7 TURTLE CT, FLEMINGTON NJ 08822
Daniel J. O'connor	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Judith Dunn	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Brian Lian	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Robin L Smith	director	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Neil Morton	officer: SVP, Chief Business Officer	C/O APRICUS BIOSCIENCES, INC., 11975 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Richard W Pascoe	director, officer: CEO & Secretary	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Alexander J Denner	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Sarissa Capital Domestic Fund Lp	10 percent owner	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830